Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | GPX4 | P36969 | 3/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276413 | 0.86 | CACNA2D1 (0.53) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL17281592 | 0.86 | CACNA2D1 (0.48) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL17276300 | 0.85 | CNR1 (0.49) | CNR1CYP3A4CYP3A5CACNA2D1CACNB1 | |
| SCHEMBL19078759 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL17276706 | 0.82 | GPX4 (0.52) | CYP3A4CYP3A5FAAHMGLLGPX4 | |
| SCHEMBL17276651 | 0.81 | GPX4 (0.56) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL17276663 | 0.80 | PLA2G7 (0.46) | — | |
| SCHEMBL17276788 | 0.79 | GPX4 (0.51) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL17276325 | 0.78 | MGLL (0.57) | CYP3A4CYP3A5CACNA2D1CACNB1CACNA1B | |
| SCHEMBL19065750 | 0.78 | MGLL (0.47) | CNR1CYP3A4CYP3A5CACNA2D1CACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | CNR1 193/4885CYP3A4 976/4885CYP3A5 728/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | CNR1 193/4885CYP3A4 976/4885CYP3A5 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.